Heptares Therapeutics Ltd has elected Roger Perlmutter to its board of directors as a non-executive director. Dr Perlmutter is the former executive vice president for research and development at Amgen Inc. Prior to this, he was executive vice president of worldwide basic research and preclinical development at Merck & Co. He joined Merck in 1997 from the University of Washington in Seattle where he was professor and founding chairman of the Department of Immunology.
Heptares is researching and developing new medicines that target the G protein-coupled receptor family of proteins.
Heptares announced the appointment on 22 October 2012.
Copyright 2012 Evernow Publishing Ltd